RxDoctor Payments Data

Allison Johns

Endocrinology, Diabetes & Metabolism · Cincinnati, OHNPI 1598129918

Payments from drug & device makers

$1,051in general payments, 2019–2025

Across 64 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$276
  • Lilly USA, LLC$118
  • Corcept Therapeutics$95
  • Pfizer$81
  • Insulet Corporation$65
  • Boehringer Ingelheim$61
  • plus $355 from 11 others

What the payments were for

  • Food & beverage$1,051100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,051 in reported general payments places this provider in the 45th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$31,457
Medicare patients
121
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$132,478
MounjaroTirzepatide66$85,965
Teriparatide24$62,892
JardianceEmpagliflozin31$36,547
TrulicityDulaglutide36$35,500
Tresiba Flextouch U-200Insulin Degludec19$28,350
Humalog Kwikpen U-200Insulin Lispro17$21,691
JanuviaSitagliptin Phosphate18$17,518
TradjentaLinagliptin21$14,904
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$13,898
Tresiba Flextouch U-100Insulin Degludec18$12,537
Lantus SolostarInsulin Glargine,hum.Rec.Anlog67$8,776
Humalog Kwikpen U-100Insulin Lispro18$5,586
Insulin Lispro Kwikpen U-100Insulin Lispro13$4,858
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic30$2,826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$276$132,478100 claims
Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro$118$123,566122 claims
Boehringer IngelheimJardiance, Tradjenta$61$51,45252 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →